<p><strong>公司在 2026 年以重新煥發的商業動力和在美國和加拿大的關鍵商業任命進入新階段</strong></p>
<p>温尼伯，曼尼托巴省，2026 年 2 月 12 日（環球新聞通訊社）——Kane Biotech Inc.（TSX-V:KNE）（“Kane Biotech”、“Kane” 或 “公司”）今天宣佈其 revyve®抗菌傷口凝膠產品線在美國和加拿大恢復商業活動，並任命兩位經驗豐富的行業領袖推動北美的業務發展。</p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/c571cd78-61af-4117-9a20-7a506a64ae40/image001.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="175" height="227" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/c571cd78-61af-4117-9a20-7a506a64ae40/image001.png"/></p>
<p><em>美國 FDA 510(k) 批准和加拿大衞生部批准的 revyve 抗菌傷口凝膠及 revyve 抗菌傷口凝膠噴霧</em></p>
<p><strong>在美國和加拿大的商業重啓</strong>：</p>
<p>在美國，Kane 已與 Medstream Healthcare Solutions, LLC（佛羅里達州多瓦爾）和 Patient Care Medical（德克薩斯州奧斯汀）簽署了非獨佔的分銷/銷售協議，預計近期將進行首次發貨。</p>
<p>在加拿大，Kane 通過將與 Best Buy Medical Canada 的分銷協議轉換為非獨佔安排，恢復了商業活動，並開展了針對性的銷售和取樣活動。儘管迄今為止在兩個國家的銷售額並不顯著，但這標誌着 Kane 商業引擎的有意義重啓。</p>
<p>“我們正在執行重置 Kane Biotech 的承諾，採用嚴謹的市場策略，” Kane Biotech 的臨時首席執行官 Robert Huizinga 博士表示。“我們將繼續生成科學信譽、臨牀驗證，並以此為基礎建立商業基礎設施。”</p>
<p><strong>戰略管理任命：</strong></p>
<p>為了支持這一增長階段，Kane 任命了兩位業務發展副總裁：</p>
<ul>
<li>Sherida (Kay) Watkins Weaver，美國業務發展副總裁。Kay 在傷口護理商業化方面擁有超過 20 年的經驗，包括在 Omeza 和 Relevate Health 的領導角色。她在醫療系統、長期護理和家庭健康市場中領導市場準入、報銷和採用策略。</li>
<li>Patti Burke-Martin，加拿大業務發展副總裁。Patti 是國家傷口護理領域的領導者，曾在 EO2 Concepts、Coloplast 和 ConvaTec 擔任高級職務。她在建立高效團隊和推動先進傷口護理技術在加拿大的採用方面有着良好的業績記錄。</li>
</ul>
<p>“Kay 和 Patti 在各自市場中帶來了深厚的專業知識和可信賴的關係，” Huizinga 博士補充道。“他們的領導將對我們擴展分銷網絡和支持 revyve 的日益採用至關重要。”</p>
<p><strong>關於 Kane Biotech Inc.（TSX-V:KNE）</strong></p>
<p>Kane Biotech 正在商業化和開發新型傷口護理治療方法，以破壞生物膜並改善癒合結果。生物膜是導致傷口抗生素耐藥性的主要因素之一，造成嚴重的臨牀後果和顯著的成本。revyve®同時針對生物膜和傷口細菌。revyve®抗菌傷口凝膠和 revyve®抗菌傷口凝膠噴霧已獲得美國 FDA 510(k) 批准。revyve®抗菌傷口凝膠也獲得了加拿大衞生部的批准。欲瞭解更多信息，請訪問 revyvegel.com 或 revyvegel.ca。</p>
<p><strong>加入 Kane 的分銷列表和社交媒體：</strong></p>
<p>要獲取最新動態，請點擊此處註冊公司的電子郵件分銷列表。</p>
<p><strong>關注 Kane</strong></p>
<p><strong>網站：</strong> kanebiotech.com</p>
<p><strong>LinkedIn：</strong> https://www.linkedin.com/company/kanebiotech/</p>
<p><strong>演示文稿：</strong> https://kanebiotech.com/publications-posters/</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>更多信息：</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dr. Robert Huizinga</strong> 臨時首席執行官<br/>Kane Biotech Inc.<br/>rhuizinga@kanebiotech.com<br/>(780) 970-1100</td>
<td><strong>Ray Dupuis</strong> 首席財務官<br/>Kane Biotech Inc.<br/>rdupuis@kanebiotech.com<br/>(204) 298-2200</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p><em>無論是 TSX 風險投資交易所還是其監管服務提供者（該術語在 TSX 風險投資交易所的政策中有定義）均不對本公告的充分性或準確性承擔責任。</em></p>
<p><em>關於前瞻性信息的警告</em></p>
<p><em>本新聞稿包含關於 Kane Biotech Inc.的某些聲明，這些聲明構成適用證券法下的前瞻性信息。這些聲明反映了管理層當前的信念，並基於目前可用的信息。某些重要因素或假設在做出前瞻性聲明時被應用，實際結果可能與這些聲明中表達或暗示的結果有重大差異。這些風險和不確定性包括但不限於與公司的相關風險：（a）財務狀況，包括迄今為止缺乏顯著收入和對股權及其他融資的依賴；（b）業務，包括其早期發展階段、政府監管、產品市場接受度、快速技術變革和對關鍵人員的依賴；（c）知識產權，包括公司保護其知識產權的能力和對其戰略合作伙伴的依賴；以及（d）資本結構，包括其普通股不支付股息、普通股市場價格的波動性和上市公司成本。有關這些及其他風險和不確定性的更多信息，請參閲公司向適用證券監管機構提交的披露文件，詳見 www.sedarplus.ca。公司警告上述可能影響未來結果的因素列表並非</em> <em>詳盡無遺。</em></p>
<p>本公告附帶的照片可在</p>
<p>https://www.globenewswire.com/NewsRoom/AttachmentNg/c571cd78-61af-4117-9a20-7a506a64ae40</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMU16VTBPU00zTkRJeU1qY3dJekl3T1RBMU5EST0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMU16VTBPU00zTkRJeU1qY3dJekl3T1RBMU5EST0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/Njc3NGE2NDgtY2U5ZC00ZDQ4LTkyZjUtOWQ3NjgwMmMyZGY3LTExMDIxMTMtMjAyNi0wMi0xMi1lbg==/tiny/Kane-Biotech-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/Njc3NGE2NDgtY2U5ZC00ZDQ4LTkyZjUtOWQ3NjgwMmMyZGY3LTExMDIxMTMtMjAyNi0wMi0xMi1lbg==/tiny/Kane-Biotech-Inc-.png"/></p>

標普生物技術 ETF - SPDR

醫療業 ETF - Vanguard

醫藥突破 ETF - ALPS

<p>Kane Biotech Inc. 已在美國和加拿大恢復其 revyve® 抗菌傷口凝膠的商業活動，並任命了兩位經驗豐富的領導者以增強業務發展。該公司已在美國簽署了分銷協議，並將其在加拿大的協議轉換為非獨佔安排。臨時首席執行官 Dr. Robert Huizinga 強調了以有序的市場策略重置公司的重要性。新任副總裁 Kay Watkins Weaver 和 Patti Burke-Martin 帶來了豐富的傷口護理商業化經驗。Kane Biotech 旨在通過其產品解決生物膜問題並改善癒合效果</p>

<p><strong>Company enters 2026 with renewed business momentum and key commercial appointments in the U.S. and Canada</strong></p>
<div class="lb-trans"><p><strong>公司在 2026 年以重新煥發的商業動力和在美國和加拿大的關鍵商業任命進入新階段</strong></p>
</div><p>WINNIPEG, Manitoba, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces the resumption of commercial activities in both the United States and Canada for its revyve® Antimicrobial Wound Gel product line, alongside the appointment of two seasoned industry leaders to drive business development across North America.</p>
<div class="lb-trans"><p>温尼伯，曼尼托巴省，2026 年 2 月 12 日（環球新聞通訊社）——Kane Biotech Inc.（TSX-V:KNE）（“Kane Biotech”、“Kane” 或 “公司”）今天宣佈其 revyve®抗菌傷口凝膠產品線在美國和加拿大恢復商業活動，並任命兩位經驗豐富的行業領袖推動北美的業務發展。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/Resource/Download/c571cd78-61af-4117-9a20-7a506a64ae40/image001.png" alt="" original-src="https://ml.globenewswire.com/Resource/Download/c571cd78-61af-4117-9a20-7a506a64ae40/image001.png"/></p>
<p><em>US FDA 510(k) cleared and Health Canada approved revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray</em></p>
<div class="lb-trans"><p><em>美國 FDA 510(k) 批准和加拿大衞生部批准的 revyve 抗菌傷口凝膠及 revyve 抗菌傷口凝膠噴霧</em></p>
</div><p><strong>Commercial Restart in the U.S. and Canada</strong>:</p>
<div class="lb-trans"><p><strong>在美國和加拿大的商業重啓</strong>：</p>
</div><p>In the U.S., Kane has signed non-exclusive distribution/sales agreements with Medstream Healthcare Solutions, LLC (Dorval, FL) and Patient Care Medical (Austin, TX) with initial shipments expected in the near term.</p>
<div class="lb-trans"><p>在美國，Kane 已與 Medstream Healthcare Solutions, LLC（佛羅里達州多瓦爾）和 Patient Care Medical（德克薩斯州奧斯汀）簽署了非獨佔的分銷/銷售協議，預計近期將進行首次發貨。</p>
</div><p>In Canada, Kane has resumed commercial activity by converting its distribution agreement with Best Buy Medical Canada to a non-exclusive arrangement, along with targeted sales and sampling initiatives. While sales to date in both countries are not material, they mark a meaningful restart of Kane’s commercial engine.</p>
<div class="lb-trans"><p>在加拿大，Kane 通過將與 Best Buy Medical Canada 的分銷協議轉換為非獨佔安排，恢復了商業活動，並開展了針對性的銷售和取樣活動。儘管迄今為止在兩個國家的銷售額並不顯著，但這標誌着 Kane 商業引擎的有意義重啓。</p>
</div><p>“We are executing on our commitment to reset Kane Biotech using a disciplined market approach,” said Dr. Robert Huizinga, Interim CEO of Kane Biotech. “We will continue to generate scientific credibility, clinical validation and with that, the commercial infrastructure.”</p>
<div class="lb-trans"><p>“我們正在執行重置 Kane Biotech 的承諾，採用嚴謹的市場策略，” Kane Biotech 的臨時首席執行官 Robert Huizinga 博士表示。“我們將繼續生成科學信譽、臨牀驗證，並以此為基礎建立商業基礎設施。”</p>
</div><p><strong>Strategic Management Appointments:</strong></p>
<div class="lb-trans"><p><strong>戰略管理任命：</strong></p>
</div><p>To support this next phase of growth, Kane has appointed two Vice Presidents of Business Development:</p>
<div class="lb-trans"><p>為了支持這一增長階段，Kane 任命了兩位業務發展副總裁：</p>
</div><ul>
<li>Sherida (Kay) Watkins Weaver, Vice President of Business Development, United States. Kay brings over 20 years of experience in wound care commercialization, including leadership roles at Omeza and Relevate Health. She has led market access, reimbursement, and adoption strategies across health systems, long-term care, and home health markets.</li>
<li>Patti Burke-Martin, Vice President of Business Development, Canada. Patti is a national wound care leader with senior roles at EO2 Concepts, Coloplast, and ConvaTec. She has a proven track record in building high-performing teams and driving adoption of advanced wound care technologies across Canada.</li>
</ul>
<div class="lb-trans"><ul>
<li>Sherida (Kay) Watkins Weaver，美國業務發展副總裁。Kay 在傷口護理商業化方面擁有超過 20 年的經驗，包括在 Omeza 和 Relevate Health 的領導角色。她在醫療系統、長期護理和家庭健康市場中領導市場準入、報銷和採用策略。</li>
<li>Patti Burke-Martin，加拿大業務發展副總裁。Patti 是國家傷口護理領域的領導者，曾在 EO2 Concepts、Coloplast 和 ConvaTec 擔任高級職務。她在建立高效團隊和推動先進傷口護理技術在加拿大的採用方面有着良好的業績記錄。</li>
</ul>
</div><p>“Kay and Patti bring deep expertise and trusted relationships in their respective markets,” added Dr. Huizinga. “Their leadership will be instrumental as we expand our distribution network and support the growing adoption of revyve.”</p>
<div class="lb-trans"><p>“Kay 和 Patti 在各自市場中帶來了深厚的專業知識和可信賴的關係，” Huizinga 博士補充道。“他們的領導將對我們擴展分銷網絡和支持 revyve 的日益採用至關重要。”</p>
</div><p><strong>About Kane Biotech Inc. (TSX-V:KNE)</strong></p>
<div class="lb-trans"><p><strong>關於 Kane Biotech Inc.（TSX-V:KNE）</strong></p>
</div><p>Kane Biotech is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost. revyve® addresses both biofilms and wound bacteria. revyve® Antimicrobial Wound Gel and revyve® Antimicrobial Wound Gel Spray are U.S. FDA 510(k) cleared. revyve® Antimicrobial Wound Gel is also Health Canada approved. To learn more, visit revyvegel.com or revyvegel.ca.</p>
<div class="lb-trans"><p>Kane Biotech 正在商業化和開發新型傷口護理治療方法，以破壞生物膜並改善癒合結果。生物膜是導致傷口抗生素耐藥性的主要因素之一，造成嚴重的臨牀後果和顯著的成本。revyve®同時針對生物膜和傷口細菌。revyve®抗菌傷口凝膠和 revyve®抗菌傷口凝膠噴霧已獲得美國 FDA 510(k) 批准。revyve®抗菌傷口凝膠也獲得了加拿大衞生部的批准。欲瞭解更多信息，請訪問 revyvegel.com 或 revyvegel.ca。</p>
</div><p><strong>Join Kane’s Distribution List &amp; Social Media:</strong></p>
<div class="lb-trans"><p><strong>加入 Kane 的分銷列表和社交媒體：</strong></p>
</div><p>To stay informed on the latest developments, sign up for the Company’s email distribution list HERE.</p>
<div class="lb-trans"><p>要獲取最新動態，請點擊此處註冊公司的電子郵件分銷列表。</p>
</div><p><strong>Follow Kane</strong></p>
<div class="lb-trans"><p><strong>關注 Kane</strong></p>
</div><p><strong>Website:</strong> kanebiotech.com</p>
<div class="lb-trans"><p><strong>網站：</strong> kanebiotech.com</p>
</div><p><strong>LinkedIn:</strong> https://www.linkedin.com/company/kanebiotech/</p>
<div class="lb-trans"><p><strong>LinkedIn：</strong> https://www.linkedin.com/company/kanebiotech/</p>
</div><p><strong>Presentations:</strong> https://kanebiotech.com/publications-posters/</p>
<div class="lb-trans"><p><strong>演示文稿：</strong> https://kanebiotech.com/publications-posters/</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>For more information:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dr. Robert Huizinga</strong> Interim CEO<br/>Kane Biotech Inc.<br/>rhuizinga@kanebiotech.com<br/>(780) 970-1100</td>
<td><strong>Ray Dupuis</strong> Chief Financial Officer<br/>Kane Biotech Inc.<br/>rdupuis@kanebiotech.com<br/>(204) 298-2200</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>更多信息：</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dr. Robert Huizinga</strong> 臨時首席執行官<br/>Kane Biotech Inc.<br/>rhuizinga@kanebiotech.com<br/>(780) 970-1100</td>
<td><strong>Ray Dupuis</strong> 首席財務官<br/>Kane Biotech Inc.<br/>rdupuis@kanebiotech.com<br/>(204) 298-2200</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</div><p><em>Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.</em></p>
<div class="lb-trans"><p><em>無論是 TSX 風險投資交易所還是其監管服務提供者（該術語在 TSX 風險投資交易所的政策中有定義）均不對本公告的充分性或準確性承擔責任。</em></p>
</div><p><em>Caution Regarding Forward-Looking Information</em></p>
<div class="lb-trans"><p><em>關於前瞻性信息的警告</em></p>
</div><p><em>This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedarplus.ca. The Company cautions that the foregoing list of factors that may affect future results is not</em> <em>exhaustive.</em></p>
<div class="lb-trans"><p><em>本新聞稿包含關於 Kane Biotech Inc.的某些聲明，這些聲明構成適用證券法下的前瞻性信息。這些聲明反映了管理層當前的信念，並基於目前可用的信息。某些重要因素或假設在做出前瞻性聲明時被應用，實際結果可能與這些聲明中表達或暗示的結果有重大差異。這些風險和不確定性包括但不限於與公司的相關風險：（a）財務狀況，包括迄今為止缺乏顯著收入和對股權及其他融資的依賴；（b）業務，包括其早期發展階段、政府監管、產品市場接受度、快速技術變革和對關鍵人員的依賴；（c）知識產權，包括公司保護其知識產權的能力和對其戰略合作伙伴的依賴；以及（d）資本結構，包括其普通股不支付股息、普通股市場價格的波動性和上市公司成本。有關這些及其他風險和不確定性的更多信息，請參閲公司向適用證券監管機構提交的披露文件，詳見 www.sedarplus.ca。公司警告上述可能影響未來結果的因素列表並非</em> <em>詳盡無遺。</em></p>
</div><p>A photo accompanying this announcement is available at</p>
<div class="lb-trans"><p>本公告附帶的照片可在</p>
</div><p>https://www.globenewswire.com/NewsRoom/AttachmentNg/c571cd78-61af-4117-9a20-7a506a64ae40</p>
<div class="lb-trans"><p>https://www.globenewswire.com/NewsRoom/AttachmentNg/c571cd78-61af-4117-9a20-7a506a64ae40</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZMU16VTBPU00zTkRJeU1qY3dJekl3T1RBMU5EST0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTY1MzU0OSM3NDIyMjcwIzIwOTA1NDI="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/Njc3NGE2NDgtY2U5ZC00ZDQ4LTkyZjUtOWQ3NjgwMmMyZGY3LTExMDIxMTMtMjAyNi0wMi0xMi1lbg==/tiny/Kane-Biotech-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/Njc3NGE2NDgtY2U5ZC00ZDQ4LTkyZjUtOWQ3NjgwMmMyZGY3LTExMDIxMTMtMjAyNi0wMi0xMi1lbg==/tiny/Kane-Biotech-Inc-.png"/></p>

Kane Biotech Restarts Commercial Activities and Strengthens North American Management | KNBIF Stock News

StockTitan

標普全球醫療股指數 ETF - iShares

Jyong Biotech Ltd.

動態生物技術與基因組 ETF - Invesco

Invesco Nasdaq Biotechnology ETF

基因改革 ETF - ARK

醫療業 ETF - SPDR

紐交所高增長板生物技術指數 ETF - First Trust

生物科技 ETF - VanEck Vectors

納斯達克生物科技指數 ETF - iShares Nasdaq

美國制藥 ETF - iShares

2 倍做多納斯達克生物技術 ETF - ProShares

NKGen Biotech

Kane Biotech 重新啓動商業活動並加強其在北美的管理 | KNBIF 股票新聞